ANN ARBOR, Mich., July 5 /PRNewswire/ -- Terumo Cardiovascular Systems
Corporation (Terumo CVS) and Fresenius HemoCare GmbH announced today that they
have signed a distributor and license agreement appointing Terumo CVS the
exclusive distributor for the Fresenius C.A.T.S systems in the U.S. The
agreement takes place one year after Terumo Medical Corporation acquired 3M's
global cardiovascular business to form the subsidiary, Terumo CVS.
Terumo CVS currently manufactures, markets, and sells CAPIOX, Sarns, and
CDI brand products used in cardiac surgery to the U.S. and other global
markets. The Fresenius C.A.T.S system is used primarily in cardiac surgery,
as well as orthopedic surgery and trauma centers. The agreement will take
effect August 1, 2000.
Terumo Cardiovascular Systems is a subsidiary of Terumo Medical
Corporation, the U.S. subsidiary of Terumo Corporation of Japan. Terumo
Corporation is a premier global medical company with 1999 annual sales of
approximately $1.6 billion. Terumo Corporation manufactures, markets and
sells a wide range of medical products including syringes, needles, catheters,
and blood bags. Terumo Cardiovascular Systems is headquartered in Ann Arbor,
Michigan with manufacturing operations in Ann Arbor, as well as Elkton,
Maryland; Ashland, Massachusetts; and Tustin, California.
Fresenius HemoCare is a company of the Fresenius Health Care Group, which
achieved world-wide sales in 1999 of approx. 5 billion Euros (+15%) with some
43,000 employees, and net income of 203 million Euros (+39%). Fresenius
HemoCare provides a wide range of products and services for blood transfusion
and cell separation, infusion of solutions and pharmaceuticals. The company
also has expertise in cancer therapy and innovative adsorber processes for the
treatment of blood outside the body.
SOURCE Terumo Cardiovascular Systems